Previous Close | 15.26 |
Open | 15.64 |
Bid | 14.88 x 0 |
Ask | 14.98 x 0 |
Day's Range | 14.50 - 15.82 |
52 Week Range | 13.88 - 28.60 |
Volume | |
Avg. Volume | 147,420 |
Market Cap | 2.185B |
Beta (5Y Monthly) | 0.22 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.57 |
Earnings Date | Oct 24, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 43.00 |
Despite challenges, Sedana Medical AB (FRA:7D2A) reports its highest Q3 net sales and raises full-year sales guidance, driven by strong market performance and strategic acquisitions.
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States. Earlier this spring, Sedana Medical reported the completion of enrolment to the parallel phase III clinical trial INSPiRE-ICU 1. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.